• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Quotient Limited Selected to Join the World Economic Forum New Champions Community

    9/8/22 8:30:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email
    • The World Economic Forum's New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better future​
    • These companies champion new business models and technologies to build resilience into their businesses, industries and communities

    JERSEY, Channel Islands, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced it was selected by the World Economic Forum to join their New Champions Community.

    "We are delighted to welcome Quotient Limited as part of the New Champions Community," said Julia Devos, Head of the New Champions Community at World Economic Forum. "Quotient's innovative MosaiQ solution aims to increase laboratory efficiencies and transform patient care on a global scale. This aligns with the World Economic Forum's wider mission to improve the state of the world. We are looking forward to engaging with them and developing our partnership in the long term."

    The World Economic Forum's New Champions Community brings together purpose driven enterprises that understand that, in a rapidly changing world, preparing for the future is crucial to survive and thrive. These companies champion new business models and technologies to build resilience into their businesses, industries, and communities.

    "At Quotient, we believe access to safe blood is a human right—and innovation in blood security, clinical diagnostics, hemovigilance and transfusion medicine keeps people alive," said, Manuel O. Méndez, Chief Executive Officer of Quotient. He added, "By aligning with the World Economic Forum's New Champion Community we can do our part to go beyond technology and help build a better future for people — and innovate for life."

    About Quotient Limited

    Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. The MosaiQ solution, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. The MosaiQ solution is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, and deliver significant workflow improvements and operational cost savings to laboratories around the world. Quotient's operations are based in Switzerland, Scotland, US, and the UAE. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

    About the World Economic Forum

    The World Economic Forum is the International Organization for Public-Private Cooperation committed to changing the state of the world. Headquartered in Geneva, Switzerland, the Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas. It was established in 1971 as a not-for-profit foundation, and is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. The Forum believes that progress happens by bringing together people from all walks of life who have the drive and the influence to make positive change. Please visit https://www.weforum.org/about/new-champions for more information on the New Champions Community.

    CONTACT: Investor Relations, [email protected]; +41 22 545 52 26



    Primary Logo

    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    Financials

    Live finance-specific insights

    See more
    • Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update

      MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

      8/9/22 7:00:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th

      JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

      8/2/22 4:05:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

      Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022  MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne

      6/24/22 7:00:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

      Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

      10/26/22 7:05:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of New Board Member

      JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

      4/26/22 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer

      JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé

      11/30/21 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:51:06 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:05:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

      4 - Quotient Ltd (0001596946) (Issuer)

      2/2/23 8:30:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $QTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $QTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

      12/3/21 9:07:16 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

      8/6/21 8:50:59 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs initiated coverage on Quotient with a new price target

      Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

      6/3/21 6:30:51 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market

      JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effect no earlier than ten days after the date of that Form 25 filing. The Company expects that as a result of this voluntary delisting, the last trading day of its ordinary shares on the Nasda

      12/12/22 4:05:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Reverse Stock Split Effective Today

      JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP

      11/2/22 5:01:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Intent to Effect Reverse Stock Split

      JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when the market opens on November 3, 2022 on the Nasdaq under the existing symbol "QTNT." The Reverse Stock Split is primarily intended to bring the Company into compliance

      10/31/22 6:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Quotient Limited

      SC 13D - Quotient Ltd (0001596946) (Subject)

      2/27/23 4:14:00 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Quotient Limited (Amendment)

      SC 13D/A - Quotient Ltd (0001596946) (Subject)

      2/22/23 10:45:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Quotient Limited (Amendment)

      SC 13D/A - Quotient Ltd (0001596946) (Subject)

      2/21/23 5:03:18 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Quotient Limited

      15-12G - Quotient Ltd (0001596946) (Filer)

      6/30/23 7:56:39 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:20 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care